HLA-DQA1*05等位基因与克罗恩病患者抗TNF药物抗药抗体形成相关
该研究通过全基因组关联分析发现,HLA-DQA1*05等位基因与克罗恩病患者接受英夫利西单抗或阿达木单抗治疗后抗药抗体形成风险显著增加相关(HR 1.90)。携带该等位基因且接受英夫利西单抗单药治疗者1年免疫原性率高达92%,而不携带者接受阿达木单抗联合治疗时仅10%。
要点
- HLA-DQA1*05携带者使用抗TNF药物时抗药抗体形成风险约增2倍。
- 英夫利西单抗单药治疗且携带HLA-DQA1*05者1年免疫原性率最高达92%。
- 阿达木单抗联合免疫调节剂且不携带HLA-DQA1*05者1年免疫原性率最低为10%。
核心结论
- HLA-DQA1*05等位基因与克罗恩病患者抗TNF药物抗药抗体形成风险显著相关。
研究设计与样本
- 全基因组关联研究,发现队列1240例生物制剂初治克罗恩病患者,验证队列178例炎症性肠病患者。
主要发现
- HLA-DQA1*05增加免疫原性发生率(HR 1.90,95%CI 1.60-2.25,P=5.88×10-13)。
- 验证队列重复该关联(HR 2.00,95%CI 1.35-2.98,P=6.60×10-4)。
- 阿达木单抗治疗者HR 1.89(95%CI 1.32-2.70),英夫利西单抗治疗者HR 1.92(95%CI 1.57-2.33)。
- 抗TNF单药治疗HR 1.75(95%CI 1.37-2.22),联合免疫调节剂HR 2.01(95%CI 1.57-2.58)。
- 英夫利西单抗单药且携带HLA-DQA1*05者1年免疫原性率92%,阿达木单抗联合治疗且不携带者1年免疫原性率10%。
临床怎么用
- 对计划使用抗TNF药物的克罗恩病患者,可考虑检测HLA-DQA1*05以评估抗药抗体形成风险。
局限性
- 需随机对照生物标志物试验确定治疗前检测HLA-DQA1*05能否改善患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Anti-tumor necrosis factor (anti-TNF) therapies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated administration can induce the formation of anti-drug antibodies. The ability to identify patients at increased risk for development of anti-drug antibodies would facilitate selection of therapy and use of preventative strategies. METHODS: We performed a genome-wide association study to identify variants associated with time to development of anti-drug antibodies in a discovery cohort of 1240 biologic-naïve patients with Crohn's disease starting infliximab or adalimumab therapy. Immunogenicity was defined as an anti-drug antibody titer ≥10 AU/mL using a drug-tolerant enzyme-linked immunosorbent assay. Significant association signals were confirmed in a replication cohort of 178 patients with inflammatory bowel disease. RESULTS: The HLA-DQA1*05 allele, carried by approximately 40% of Europeans, significantly increased the rate of immunogenicity (hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.60-2.25; P = 5.88 × 10-13). The highest rates of immunogenicity, 92% at 1 year, were observed in patients treated with infliximab monotherapy who carried HLA-DQA1*05; conversely the lowest rates of immunogenicity, 10% at 1 year, were observed in patients treated with adalimumab combination therapy who did not carry HLA-DQA1*05. We confirmed this finding in the replication cohort (HR, 2.00; 95% CI, 1.35-2.98; P = 6.60 × 10-4). This association was consistent for patients treated with adalimumab (HR, 1.89; 95% CI, 1.32-2.70) or infliximab (HR, 1.92; 95% CI, 1.57-2.33), and for patients treated with anti-TNF therapy alone (HR, 1.75; 95% CI, 1.37-2.22) or in combination with an immunomodulator (HR, 2.01; 95% CI, 1.57-2.58). CONCLUSIONS: In an observational study, we found a genome-wide significant association between HLA-DQA1*05 and the development of antibodies against anti-TNF agents. A randomized controlled biomarker trial is required to determine whether pretreatment testing for HLA-DQA1*05 improves patient outcomes by helping physicians select anti-TNF and combination therapies. ClinicalTrials.gov ID: NCT03088449.
引用
- Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology. 2019. PMID: 31600487. doi:10.1053/j.gastro.2019.09.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。